Dr Campbell completed her PhD in Immunology 2018 under the supervision of Dr Aisling Dunne and Dr Jean Fletcher at Trinity College Dublin (Ireland). Her PhD research focused on immunoregulation by the anti-oxidant and anti-inflammatory enzyme, Heme Oxygenase 1 (HO-1), in human immune cells. In January 2019, she commenced her postdoctoral research position with Prof Paul Hertzog at the Centre for Innate Immunity and Infectious Diseases (CiiiD) at the Hudson Institute, and in 2022 was promoted to the role of Research Scientist. Since joining CiiiD, her research has been centred on type I interferons (IFNs) pleiotropic cytokines with well-characterised functions in anti-viral and anti-cancer immunity. Her primary research focus is currently investigating the potential of interferon epsilon (IFNε), a unique type I IFN discovered by Prof Hertzog’s lab, as a treatment for ovarian cancer. Her work in this role has contributed to an upcoming original research article (under revision, Nature), ongoing drug development with industry partners at the Hudson Institute, and the award of an NHMRC Ideas Grant to Prof Hertzog. Furthermore, during this time she has led other ongoing research including studies on the innate immune response to COVID-19, characterisation of immunoregulation by interferons in the peritoneal cavity, and identification of novel protein interactions during interferon signalling. Her main laboratory expertise lies in multicolour flow cytometry, cell culture, animal handling and pre-clinical modelling of ovarian cancer.